A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies (NCT05443126)
A Modular, Open-label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0031 in Patients With Advanced RET-altered Malignancies
🩺 Plain-English Summary (8th-Grade Level)
The aim of this study is to assess the safety, side effects and effectiveness of EP0031 (Lunbotinib) in patients with advanced RET-altered non-small cell lung cancer (NSCLC) in monotherapy and in combination with standard of care (SOC) chemotherapy.
Who can join: Review the eligibility criteria below.
Location: David Geffen School of Medicine at UCLA — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (52 Sites)
Showing the first 25 of 52 sites.
- David Geffen School of Medicine at UCLA — Los Angeles, California
- Stanford University — Stanford, California
- Georgetown University — Washington D.C., District of Columbia
- Florida Cancer Specialist — Fort Myers, Florida
- University of Miami - Sylvester Comprehensive Cancer Center — Miami, Florida
- Florida Cancer Specialists & Research Institute — West Palm Beach, Florida
- RUSH University Medical Center — Chicago, Illinois
- Northwestern University — Evanston, Illinois
- University of Kentucky — Lexington, Kentucky
- Massachusetts General Hospital — Boston, Massachusetts
- Karmanos — Detroit, Michigan
- Memorial Sloan Kettering Cancer Center — New York, New York
- NYU Langone Health — New York, New York
- The Ohio State University - Comprehensive Cancer Center — Columbus, Ohio
- Providence Portland Medical Centre — Portland, Oregon
- Thomas Jefferson University — Philadelphia, Pennsylvania
- Sarah Cannon Research Institute — Nashville, Tennessee
- MD Anderson Cancer Center — Houston, Texas
- Virginia Cancer Specialists — Fairfax, Virginia
- Washington University - School of Medicine — Seattle, Washington
- University of Washington - Fred Hutchinson Cancer Center — Seattle, Washington
- Institut Bergonié — Bordeaux,
- Centre François Baclesse — Caen,
- Centre Léon Bérard — Lyon,
- Assistance Publique - Hôpitaux de Marseille — Marseille,
📞 Contact the Study Coordinator
Phone: +44 20 3743 0992
Email: Enquires@ellipses.life
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in NSCLC
- Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy — Savannah, Georgia
- A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC — Daphne, Alabama
- Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC — La Jolla, California
- A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care — Boston, Massachusetts
- Study of Oral MRT-2359 in Selected Cancer Patients — Scottsdale, Arizona
- Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations — Phoenix, Arizona
Explore by condition: All NSCLC clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.